TDOC Stock Risk & Deep Value Analysis
Teladoc Health Inc
DVR Score
out of 10
What You Need to Know About TDOC Stock
We analyzed Teladoc Health Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran TDOC through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
TDOC Risk Analysis & Red Flags
What Could Go Wrong
Teladoc's core BetterHelp segment continues to weaken and face pricing pressure from 'better-for-less costly telehealth alternatives,' leading to an accelerating -2.5% YoY revenue decline and persistent free cash flow outflows greater than -$26.3 million per quarter, making profitable growth unattainable in the next 3-5 years.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
Medium
Red Flags
- ⚠
Q1 2026 Revenue declined 2.5% YoY, indicating erosion of market position and challenge in achieving top-line growth.
- ⚠
Q1 2026 Free Cash Flow was an outflow of -$26.3 million, signaling continued cash burn despite efficiency efforts.
- ⚠
Jefferies' price target of $6, raised post-Q1 earnings, is below the current market price of $7.61, indicating analyst skepticism about near-term upside.
- ⚠
Operating cash flow declined 40.2% YoY in Q1 2026 to $9.5 million, showing weakening cash generation from core operations.
Upcoming Risk Events
- 📅
Q2 2026 Earnings Miss (Estimated late-July / early-August 2026): If revenue decline accelerates beyond -2.5% YoY or FCF outflow widens beyond -$26.3 million, triggering further analyst downgrades and cash burn concerns.
- 📅
Increased Competition/Pricing Pressure (Ongoing, next 12-18 months): If major competitors (e.g., Amazon Clinic, CVS Health virtual offerings) aggressively price services, driving Teladoc's gross margins below 60% or causing further market share losses in key segments.
When to Reconsider
- 🚪
Exit if quarterly revenue decline accelerates beyond -5% YoY for two consecutive quarters, indicating a deepening top-line problem.
- 🚪
Sell if free cash flow outflow exceeds -$50 million for a single quarter without clear, justifiable, value-accretive investments.
- 🚪
Exit if operating margin improvement stalls or deteriorates back below -15% for two consecutive quarters, signaling a reversal in efficiency gains.
Unlock TDOC Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
If Teladoc successfully pivots its BetterHelp segment through strategic repositioning and cost efficiencies, while simultaneously accelerating chronic care management revenue via new large employer/payer contracts (e.g., >$50M annual contract), then it could re-accelerate overall revenue growth to 5%+ YoY and achieve positive free cash flow, justifying a P/S multiple re-rating from 0.4x to 2.0x within 3 years, translating to a market cap of ~$5B (from ~$2.5B revenue) and a potential 3-4x return from current levels, with further upside towards 10x if it establishes clear market leadership in integrated virtual care.
Is TDOC Stock Undervalued?
Unlock the full AI analysis for TDOC
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
TDOC Price Targets & Strategy
12-Month Target
$9.72
Bull Case
$14.44
Bear Case
$3.33
Valuation Basis
0.7x P/S multiple on projected stable FY2026 revenue of $2.5B, assuming ~180M shares outstanding.
Entry Strategy
Consider dollar-cost averaging on dips towards $7.00, which has shown some historical support. High volatility suggests cautious entry.
Exit Strategy
Take 50% profit if price reaches $10-12 range (signaling market belief in stabilization); consider stop-loss if stock falls below $6.00 and revenue decline accelerates.
Portfolio Allocation
1-3% for aggressive risk tolerance, reflecting highly speculative nature.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is TDOC Financially Healthy?
Valuation
P/E Ratio
2.00
Forward P/E
2.00
EV/EBITDA
37.08
Price/Book
1.00
Price/Sales
0.38
Profitability
Gross Margin
69.29%
Operating Margin
-8.12%
Net Margin
-6.81%
Return on Equity
-12.37%
Revenue Growth
-1.50%
EPS
$-0.96
Balance Sheet
Current Ratio
2.77
Quick Ratio
2.51
Debt/Equity
0.72
Total Debt
$1.04B
Cash & Equivalents
$781.08M
Cash Flow
Operating Cash Flow
$294.36M
Free Cash Flow
$285.46M
EBITDA
$33.10M
Other
Beta (Volatility)
2.14
Does TDOC Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Eroding
Moat Sources
3 Identified
Teladoc's moat, while present through its established ecosystem and broad service offering, is under pressure. The increasing commoditization of basic telehealth services and competitive intensity from 'better-for-less costly telehealth alternatives' (especially in mental health with BetterHelp weakness) are eroding its pricing power and requiring constant innovation to maintain differentiation. Its durability will depend on successful integration of services and sustained execution.
Moat Erosion Risks
- •Intensified competition from well-funded tech giants (e.g., Amazon, Apple) and integrated healthcare providers (e.g., Optum, CVS Health) offering similar or superior virtual care solutions.
- •Failure to sufficiently differentiate its offerings from 'better-for-less costly telehealth alternatives', leading to continued market share loss and margin compression.
- •Rapid shifts in consumer preferences or regulatory landscape that favor direct-to-consumer models or specialized point solutions over broad integrated platforms.
TDOC Competitive Moat Analysis
Sign up to see competitive advantages
TDOC Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral, leaning Bearish, with some speculative interest due to deep valuation discount.
Institutional Sentiment
Neutral, with cautious signals from analysts; Jefferies' price target of $6 is below current market price ($7.61).
Insider Activity (Form 4)
Form 4/beneficial ownership filings exist in the last 90 days, but transaction details (names, shares, value, direction) are not exposed in the provided research to make a definitive statement on specific buy/sell activity.
Options Flow
Normal options activity; no specific unusual put/call ratio or large block trades indicating institutional positioning are noted in the research.
Earnings Intelligence
Next Earnings
Estimated late-July / early-August 2026 for Q2 2026 results.
Surprise Probability
Medium, as expectations are likely low given recent performance, allowing for a potential beat on adjusted profitability metrics or stabilization in BetterHelp.
Historical Earnings Pattern
Given recent performance and challenging Q1 results, the stock typically sees a muted or negative reaction unless there is a significant upside surprise in revenue growth, FCF trajectory, or strong forward guidance.
Key Metrics to Watch
Competitive Position
Top Competitor
UNH (UnitedHealth Group - Optum)
Market Share Trend
Losing or struggling to gain market share, indicated by the -2.5% YoY revenue decline and 'broader concerns about market dominance' within a growing market.
Valuation vs Peers
Trading at a significant discount with a P/S ratio of ~0.4x compared to peer/industry averages of 2.1x-2.2x, reflecting deep market skepticism but also massive potential upside if a turnaround is successful.
Competitive Advantages
- •Broad portfolio of virtual care services (general medical, mental health, chronic care).
- •Established large network of providers and existing employer/payer client base.
- •Technological platform supporting integrated, whole-person health solutions.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive TDOC Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings (Estimated late-July / early-August 2026): If revenue shows sequential stabilization or returns to modest growth, and FCF improves towards positive, it could signal a bottom.
- •Cost Efficiency Program Update (Q3 2026): Specific details on further cost reductions or efficiency gains expected to impact Q3/Q4 2026 adjusted EBITDA, driving margin expansion.
Medium-Term (6-18 months)
- •New Major Employer/Payer Partnership (H1 2027): Announcement of a significant contract with a large insurer or employer group, explicitly targeting chronic care management, with a projected revenue impact of >$50M annually.
- •BetterHelp Stabilization/Growth (Q4 2026 - Q1 2027): If BetterHelp segment revenue returns to positive YoY growth, indicating successful pivot/reinvigoration in mental health services.
Long-Term (18+ months)
- •Integrated Whole-Person Health Platform Dominance (FY2028-2029): If Teladoc successfully integrates its multi-specialty offerings and captures >15% market share in the integrated virtual care platform segment, leading to sustained 10%+ revenue growth and 5%+ FCF margin.
- •International Expansion (FY2029): If successful penetration into key European or APAC markets adds >$500M in annual revenue run-rate with 20%+ operating margins.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for TDOC?
- ✓
Watch for Q2 2026 revenue to stabilize or show sequential growth, signaling a potential bottom in top-line performance.
- ✓
Monitor quarterly Free Cash Flow: a sustained trend towards positive FCF, or significant reduction in the -$26.3 million outflow, would validate efficiency efforts and improve financial health.
- ✓
Track BetterHelp segment revenue: A return to YoY growth in this specific segment would indicate successful repositioning and address a key competitive weakness mentioned.
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Teladoc Health Inc Makes Money
Teladoc Health provides a comprehensive suite of virtual healthcare services globally, connecting individuals with licensed healthcare professionals for general medical, mental health (primarily via its BetterHelp platform), and chronic condition management through a scalable technology platform. Its primary customers are large employers, health plans, and hospitals who pay recurring subscription fees (per-member, per-month), with some revenue also generated from per-visit fees for direct-to-consumer and additional services. The business model aims to improve access to care, lower healthcare costs, and offer integrated 'whole-person' health solutions.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Teladoc Health Inc (TDOC)?
As of May 31, 2026, Teladoc Health Inc has a DVR Score of 4.3 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Teladoc Health Inc?
Teladoc Health Inc's market capitalization is approximately $1.4B..
What is the risk level for TDOC stock?
Our analysis rates Teladoc Health Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of TDOC?
Teladoc Health Inc currently has a price-to-earnings (P/E) ratio of 2.0. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Teladoc Health Inc's revenue growing?
Teladoc Health Inc has reported revenue growth of -1.5%. Revenue has been declining, which warrants closer examination.
Is TDOC stock profitable?
Teladoc Health Inc has a profit margin of -6.8%. The company is currently unprofitable.
How often is the TDOC DVR analysis updated?
Our AI-powered analysis of Teladoc Health Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 31, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for TDOC (Teladoc Health Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.